Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals TARS
$ 72.94 -6.36%
report update icon

Quarterly report 2026-Q3
added 11-03-2026

Tarsus Pharmaceuticals Revenue | TARS

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Tarsus Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
451 M 183 M 17.4 M 25.8 M 57 M - - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
451 M 17.4 M 147 M

Quarterly Revenue Tarsus Pharmaceuticals

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
195 M 174 M 162 M 152 M 119 M 103 M 78.3 M 66.4 M 48.1 M 40.8 M 27.6 M 13.1 M 1.87 M - 2.5 M 10 M - 15.3 M 539 K 338 K 1.24 M 22 M 33.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
195 M 338 K 60.2 M

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Sutro Biopharma Sutro Biopharma
STRO
102 M $ 8.6 -1.38 % $ 73.1 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
719 M $ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
616 M $ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
543 M - -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
70.8 M $ 29.91 -4.87 % $ 3.05 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
15 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
1.11 M - -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
1.02 M $ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
74.5 M - - $ 376 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
7.5 M $ 36.89 -1.78 % $ 2.92 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
292 M $ 16.95 2.02 % $ 2.72 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
6.5 M $ 3.01 1.69 % $ 127 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
6.7 M - -1.68 % $ 283 M usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
174 K - -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
164 M - 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
1.8 M - 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
527 M - - $ 6.81 B britainBritain
22nd Century Group 22nd Century Group
XXII
17.6 M $ 0.32 -19.83 % $ 58.9 K usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
8.29 M - - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
401 K - - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
36.4 M $ 926.42 -1.66 % $ 56.8 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
13.1 M $ 2.33 -7.25 % $ 19.8 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
460 M $ 21.01 -4.16 % $ 23 B chinaChina
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
64.6 M - -2.54 % $ 57.2 M usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
67.4 M $ 1.37 0.74 % $ 98.5 M usaUSA
Zoetis Zoetis
ZTS
9.47 B $ 78.81 -2.47 % $ 34.9 B usaUSA
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
178 M - -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
8.78 M - - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
2.98 M $ 1.47 -4.55 % $ 2.5 M usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
139 M - - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
148 K - - $ 1.94 B canadaCanada
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
74 M - - $ 10.9 B usaUSA
Zogenix, Inc. Zogenix, Inc.
ZGNX
13.6 M - -4.97 % $ 664 M usaUSA
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
146 K - -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
9.77 M $ 3.71 -1.72 % $ 1.19 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
276 M $ 57.41 -1.46 % $ 2.89 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
68.6 M $ 8.37 -5.64 % $ 1.16 B usaUSA
Veracyte Veracyte
VCYT
517 M $ 25.08 0.16 % $ 1.97 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
10.7 K $ 24.72 -4.35 % $ 2.79 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
216 M $ 3.44 -6.27 % $ 203 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
1.27 M $ 0.16 -12.33 % $ 6.09 M usaUSA